Study shows positive improvement on combined treatment for wet AMD

Article

OPT-302 combined with ranibizumab: covering all the VEGF bases for superior visual gains compared with ranibizumab alone in wet AMD

A phase 2b study1 of OPT-302 (Opthea Ltd.), an anti-vascular endothelial growth factor (VEGF)-C/-D “trap” agent, in combination with ranibizumab (Lucentis, Genentech Inc.) to treat wet age-related macular degeneration (AMD) showed that administering the 2 VEGF inhibits drugs resulted in a larger improvement in visual acuity (VA) after 24 weeks compared with ranibizumab alone.

The rationale behind this treatment was to also inhibit VEGF-C and VEGF-D using OPR-302 in addition to VEGF-A, which ranibizumab, the standard of care for wet AMD, inhibits.

The randomized, double-masked, sham-controlled trial included patients with treatment-naïve neovascular AMD who were treated at 109 sites in Europe, Israel, and the US.

The patients were randomized to 6, every-4-week intravitreal injections of 0.5 mg OPT-302, 2.0 mg OPT-302, or sham plus intravitreal 0.5 mg ranibizumab. The primary outcome was the mean change in Early Treatment Diabetic Retinopathy Study best-corrected VA (BCVA) at 24 weeks. The secondary outcomes were the percentages of patients who gained or lost 15 or more letters of BCVA at 24 weeks compared with baseline and the changes in the central subfield thickness and the intra-retinal and sub-retinal fluid on spectral-domain optical coherence tomography (SD-OCT) images.

OPT-302 results

A total of 366 patients were included from December 1, 2017, to November 30, 2018. Patients were randomized to receive 0.5 mg OPT-302 (n=122), 2.0 mg OPT-302 (n=123), or sham (n=121), respectively.

The investigators reported that the 2.0-mg OPT-302 group had a significant (p=0.01) BCVA gain that was superior to sham (+14.2 ± 11.61 versus +10.8 ± 11.52 letters, respectively). The BCVA gain in the 0.5-mg OPT-302 group did not reach significance (p=0.83) compared with the sham group (+9.44 ± 11.32 letters, respectively). The structural outcomes favored both OPT-302 dosage groups. Adverse events were similar across groups, with 16 (13.3%), 7 (5.6%), and 10 (8.3%) participants in the low-dose, high-dose, and sham groups, respectively, developing at least one serious adverse event. Two unrelated deaths both occurred in the sham arm.

The investigators concluded that “significantly superior vision gain was observed with OPT-302 2.0 mg combination therapy versus the standard of care, with favorable safety.”

Opthea, according to a company press release, is currently conducting two global confirmatory phase 3 studies, ShORe (2 mg OPT-302 + 0.5 mg ranibizumab), and COAST (2 mg OPT-302 + 2 mg aflibercept [Eylea, Regeneron]). The primary endpoint for both studies is the superiority in VA gains at 12 months for the combination therapy compared with standard-of-care monotherapy.

Reference:
1. Jackson TL, Slakter J,Buyse M, et al. A randomized controlled trial of OPT-302, a VEGF-C/D inhibitor for neovascular age-related macular degeneration. Ophthalmology. Published online Feb. 5, 2023; DOI:https://doi.org/10.1016/j.ophtha.2023.02.001
Recent Videos
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
Mile Brujic, OD, FAAO; Nate Lighthizer, OD, FAAO; Brianna Rhue, OD, FAAO, FSLS; Ben Casella, OD; and Ben Gaddie, OD, FAAO shared their insights from the conference.
Agatha Sleboda, OD; Arti Shah, OD, FAAO; and Kent J. Nozacki, OD provide the best tips that they give to their patients during natural disasters events in light of the recent Greater Los Angeles wildfires.
Optometrists local to the Los Angeles area overview their efforts to continue providing support to patients affected by January's wildfires.
© 2025 MJH Life Sciences

All rights reserved.